Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021051 (immunodeficiency)
 71,517 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new reverse transcriptase (RT) inhibitor was extracted and purified from the red alga Schizymenia pacifica. The chromatographic behavior and chemical properties of this sea algal extract (SAE) suggest that it is a sulfated polysaccharide having a molecular weight of approximately 2,000,000. SAE is composed of galactose (73%), sulfonate (20%), and 3,6-anhydrogalactose (0.65%). SAE is a member of the lambda-carrageenan family, based on its infrared spectrum and products of hydrolysis. SAE selectively inhibited human immunodeficiency virus (HIV) RT and replication in vitro. When MT-4 cells were treated with more than 10(4) inhibitory units (IU) of SAE per ml after HIV infection, significant inhibition of viral antigen synthesis was observed. Furthermore, more than 90% of cells were viable in the cultures exposed to 4 X 10(4) to 8 X 10(4) IU of SAE per ml, while almost all the MT-4 cells in the control culture had died by 10 days after HIV infection. The inhibitory effect of SAE on HIV replication was confirmed by plaque reduction assays. The 50% inhibitory dose of SAE was 9.5 x 10(3) IU/ml. Chondroitin sulfate A, dermatan sulfate, heparan sulfate, keratan polysulfate, and heparin also inhibited the RT of avian myeloblastosis virus. SAE immediately inhibited RT activity when added to an assay mixture after the start of the reaction.
 ...
PMID:Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae. 244 20

Different isolates (HTLV-IIIB, LAV1 and ARV2) of human immunodeficiency virus (HIV) were cloned by a plaque-forming assay using MT-4 cells. The reverse transcriptase (RT) activity and plaque-forming unit (PFU) titers of all viral preparations were assayed. PFU/RT values, which indicate the relative proportions of incomplete and infectious viruses, were used for determination of viral infectivity. High values were obtained mainly for clones of HTLV-IIIB and LAV1, and low values for ARV2-derived clones, suggesting that ARV2 and its clones were genetically less infectious. For studies on cytocidal effects of the viruses, four clones of HTLV-IIIB, LAV1 and ARV2 were selected that had similar PFU/RT (infectivity) values for proliferation in infected MT-4 cells. When compared at the same dose (MOI), one clone (HTLV-IIIB-C-2) was found to be more cytocidal than the others. Furthermore, plaques induced by HTLV-IIIB-C-2 were larger than those induced by other clones, suggesting that the release of progeny from HTLV-IIIB-C-2-infected cell and their proliferation were the most efficient. Among the cloned viruses tested, three were found to induce strong cytopathic changes (fusion and ballooning) selectively in MT-4 cells. Thus, the infectivity, proliferation and cytopathic fusion-effects were proposed to be encoded by the viral genome and be separable by the plaque-cloning method.
 ...
PMID:Clonal analysis of functional differences among strains of human immunodeficiency virus (HIV). 245 Aug 87

The sulfated polysaccharides dextran sulfate and heparin have proved to be potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) in vitro. Dextran sulfate (Mr 5000) and heparin (Mr 15,000) completely protected MT-4 cells against HIV-1-induced cytopathogenicity at a concentration of 25 micrograms/ml. Their 50% inhibitory concentrations were 9.1 micrograms/ml (dextran sulfate) and 7.0 micrograms/ml (heparin), respectively. No toxicity for the host cells was observed with these compounds at a concentration of 625 micrograms/ml. The anti-HIV-1 activity of heparins of various molecular weights correlated well with their anticoagulant activity. On the other hand, with dextran sulfates of low molecular weight (5000, 8000) a significant inhibitory effect on HIV-1 was achieved at a concentration that was not markedly inhibitory to the blood coagulation process. Dextran sulfate and heparin were not inhibitory to HIV-1 reverse transcriptase unless they were used at concentrations in excess of those that inhibited HIV-1 replication. They were highly effective against HIV-1 replication even when present only during the 2-hr virus adsorption period. Studies using radiolabeled HIV-1 virions indicated that dextran sulfate and heparin inhibit virus adsorption to the host cells.
 ...
PMID:Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. 245 6

The first step in the replicative cycle of human immunodeficiency virus type 1 (HIV-1) is binding of the virions to the cellular CD4 receptor. This process may be considered as an important target for chemotherapeutic agents against acquired immune deficiency syndrome (AIDS). A method has now been devised whereby virion binding to the cell membrane was visualized by an indirect immunofluorescence assay using human anti-HIV-1 serum, rabbit anti-human-IG-F(ab')2-fluorescein isothiocyanate, and flow cytometry. Heparin, dextran sulfate, and pentosan polysulfate suppressed HIV-1 binding to MT-4 cells at concentrations that protected the cells against HIV-1 cytopathogenicity. Dextran and dermatan sulfate, two compounds that are inactive against HIV-1, had no inhibitory effect on the binding of HIV-1 to the cells. The potent and selective HIV-1 inhibitor azidothymidine (AZT) did not affect virus binding to the cells, whereas suramin partially blocked HIV-1 binding to the cells at concentrations that fully protected MT-4 cells against destruction of HIV-1. Our immunofluorescence assay thus demonstrated that suramin not only acts as an inhibitor of reverse transcriptase but also interferes with virus-cell binding. Also, Evans blue, an anionic dye structurally related to suramin, partially inhibited HIV-1 attachment to the cells. The present method permits a quantitative determination of the inhibitory effect of anti-HIV-1 agents on virion-cell binding.
 ...
PMID:Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells. 246 2

Several sulfated oligo- or polysaccharides such as pentosan polysulfate, fucoidan, dextran sulfate, heparin and iota-, kappa- and lambda-carrageenans proved to be potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) in vitro. The most potent anti-HIV-1 activity was recorded for the oligosaccharide pentosan polysulfate, its 50% antiviral effective dose (ED50) being 0.19 microgram/ml in MT-4 cells. It inhibited HIV-1 antigen expression in HUT-78 cells at an ED50 of 0.02 microgram/ml, and complete inhibition of HIV-1 antigen expression was obtained at a concentration of 4.0 micrograms/ml. No toxicity for MT-4 cells was observed with pentosan polysulfate at a concentration of 2500 micrograms/ml. The anticoagulant activity of pentosan polysulfate was more than ten-fold lower than that of heparin (14.4 and 177 U/mg, respectively). In fact, pentosan polysulfate achieved its anti-HIV-1 activity at a concentration that is 370-fold below its anticoagulant threshold (1 U). Pentosan polysulfate inhibits virus adsorption to the cells, as was demonstrated by monitoring the association of radiolabeled HIV-1 virions with MT-4 cells.
 ...
PMID:Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. 246 36

Several cholic acid derivatives such as taurolithocholic acid, lithocholic acid 3-sulfate, taurolithocholic acid 3-sulfate, and glycolithocholic acid 3-sulfate were shown to inhibit selectively the replication of human immunodeficiency virus type 1 (HIV-1) in vitro. These compounds completely protected MT-4 cells against HIV-1-induced cytopathogenicity at a concentration of 100 micrograms/ml, whereas no toxicity for the host cells was observed at 200 micrograms/ml. They also inhibited HIV-1 antigen expression in HIV-1-infected CEM cells. The bile acids (cholic acid, deoxycholic acid, chenodeoxycholic acid, and lithocholic acid) did not show any inhibitory effect on HIV-1 replication at concentrations that were not toxic to the host (MT-4) cells. From a structure-function analysis of a number of cholic acid derivatives, the presence of either a sulfonate (as in the tauro conjugates) or a sulfate group as well as the "litho" configuration appeared to be necessary for the expression of anti-HIV-1 activity. The active cholic acid derivatives did not directly inactivate the virus particles at the concentrations that were not toxic to the host cells. Lithocholic acid 3-sulfate, taurolithocholic acid 3-sulfate, and glycolithocholic acid 3-sulfate, but not taurolithocholic acid, partially inhibited virus adsorption to MT-4 cells. These three compounds were also inhibitory to the reverse transcriptase activity associated with HIV-1.
 ...
PMID:Selective activity of several cholic acid derivatives against human immunodeficiency virus replication in vitro. 230 4

Tumor necrosis factor (TNF), a monokine initially described as a tumoricidal agent, facilitated the replication of human immunodeficiency virus (HIV) in vitro. The viability of human T-cell line MOLT-4/HIV, chronically infected with HIV, was affected by the addition of a low dose (10 ng/ml) of recombinant TNF-alpha (rTNF-alpha), while uninfected MOLT-4 cells were resistant to treatment with rTNF-alpha at concentrations up to 1,000 ng/ml. A marked increase in the level of HIV-specific RNA was detected in MOLT-4/HIV cells as early as 1 h after exposure to rTNF-alpha and reached almost maximum level within 6 h. Production of HIV particles from MOLT-4/HIV was also increased at 6 h after treatment with rTNF-alpha. Nearly identical phenomena were observed in CCRF-CEM/HIV, Jurkat/HIV, and H9/HIV cells, although the sensitivity of these cell lines to rTNF-alpha varied. A human T-lymphotropic virus type 1-infected cell line, MT-4, was insensitive to treatment with rTNF-alpha.
 ...
PMID:Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication. 247 Sep 17

Dextran sulphate is a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1). Its anti-HIV-1 activity has been investigated under varying experimental conditions. MT-4 cells were infected with HIV-1 at different multiplicities of infection (MOI), and treated with either dextran sulphate, 3'-azido-2',3'-dideoxythymidine (AZT), or anti-HIV-1 serum obtained from an ARC patient. Dextran sulphate suppressed HIV-1 replication (as monitored by viral antigen expression) when the MOI was 0.01 or 0.1. It was ineffective at an MOI of 1.0. The anti-HIV-1 serum was only partially effective at an MOI of 0.01 and ineffective at an MOI of 0.1 or 1.0. AZT proved effective at all three MOIs. Co-cultures of uninfected and HIV-1-infected MT-4 cells were protected against destruction by dextran sulphate at a concentration of 10 and 100 micrograms/ml. To fully suppress viral antigen expression a concentration of 100 micrograms/ml was needed. When used at this concentration, a 1-h contact of dextran sulphate with the cells during the virus adsorption period sufficed to suppress HIV-1 antigen expression. In this sense, dextran sulphate behaved like the anti-HIV-1 serum. Dextran sulphate also behaved like OKT-4A in that they both inhibited HIV-1 attachment to the MT-4 cells, whereas OKT-4 failed to do so. However, dextran sulphate did not affect the binding of OKT-4A to the cells. The present results support the concept that dextran sulphate owes its anti-HIV-1 activity mainly to inhibition of virus binding to its target cells. The anti-HIV-1 activity of dextran sulphate is highly dependent on its sulphate content.
 ...
PMID:Anti-HIV activity of dextran sulphate as determined under different experimental conditions. 247 75

A modification of the MT-4 cell plaque assay for human immunodeficiency virus (HIV) is described, which gave reproducible results with all 4 HIV-1 strains and the two HIV-2 strains that were used. The main feature of this new method is the use of a tetrazolium (MTT) staining procedure. The number of plaques read after 4-6 days was essentially the same as the number of infectious units derived from the 50% cell culture infective dose (CCID50) in MT-4 suspension cultures. For a selected group of antiviral compounds the 50% plaque-inhibitory doses were comparable with the 50% inhibitory doses (ID50) in suspension cultures. In the plaque assay HIV-1 (HTLV-IIIB) and HIV-2 (LAV-2ROD) were equally susceptible to azidothymidine (AZT), and the same was true for didehydrodideoxythymidine (D4T). For these compounds it was irrelevant whether they were already present during the initial HIV adsorption phase or added immediately thereafter. Pentosan polysulfate proved about 20-fold more inhibitory to HIV-2 than HIV-1. There was a 5-fold increase in activity if present during the virus adsorption stage.
 ...
PMID:Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds. 248 43

Two novel, semi-automated assays for the assessment of compounds for activity against human immunodeficiency virus (HIV) are described. One assay uses quantitation of DNA by fluorescence to monitor reversal by test compounds of HIV-induced growth inhibition. The second assay measures the amount of HIV p24 by an indirect immunofluorescent technique. Both assays are sufficiently sensitive to allow multiple sampling of 96-well plates. Intra- and inter-assay variability were within acceptable limits. The two assays provide comparable results for given compounds. Retrovir (3'-azido, 3'-deoxythymidine, AZT) protected MT4 cells from HIV-induced growth inhibition, and inhibited the production of HIV p24. Consistent with the results of others, the anti-HIV potency of AZT was dependent on the concentration of the infecting virus. Interestingly, AZT-protected, HIV-infected MT4 cells grew faster than mock-infected MT4 cells, and inclusion of Interleukin 2 in the assay eliminated this effect.
 ...
PMID:Anti-HIV compound assessment by two novel high capacity assays. 249 28


<< Previous 1 2 3 4 5 6 7 8 9 10